COVID-19 and patients with immune-mediated inflammatory diseases undergoing pharmacological treatments: a rapid living systematic review
AUTOR(ES)
Rocha, Aline Pereira da; Atallah, Álvaro Nagib; Pinto, Ana Carolina Pereira Nunes; Rocha-Filho, César Ramos; Milby, Keilla Martins; Civile, Vinicius Tassoni; Carvas Junior, Nelson; Reis, Felipe Sebastião de Assis; Ferla, Laura Jantsch; Ramalho, Gabriel Sodré; Trevisani, Giulia Fernandes Moça; Puga, Maria Eduarda dos Santos; Trevisani, Virgínia Fernandes Moça
FONTE
Sao Paulo Med. J.
DATA DE PUBLICAÇÃO
2020-12
RESUMO
ABSTRACT BACKGROUND: Patients with immune-mediated inflammatory diseases (IMID) are at increased risk of infection. OBJECTIVE: To assess whether patients undergoing pharmacological treatment for IMID present higher risk of worse outcomes when diagnosed with COVID-19. DESIGN AND SETTING: Rapid systematic review conducted in the medical school of the Federal University of São Paulo (SP), Brazil. METHODS: We searched CENTRAL, MEDLINE, EMBASE, LILACS, SCOPUS, Web of Science, L·OVE, ClinicalTrials.gov and WHO-ICTRP for studies evaluating patients diagnosed with COVID-19 who were undergoing pharmacological treatment for IMID. Two authors selected studies, extracted data and assessed risk of bias and certainty of evidence, following the Cochrane recommendations. RESULTS: We identified 1,498 references, from which one cohort study was included. This compared patients with and without rheumatic diseases (RD) who all had been diagnosed with COVID-19. Those with RD seemed to have higher chances of hospitalization and mortality, but no statistical difference was detected between the groups: hospitalization: odds ratio (OR) 1.17; 95% confidence interval (CI) 0.6 to 2.29; mortality rate: OR 1.53; 95% CI 0.33 to 7.11 (very low certainty of evidence). Patients with RD were three times more likely to require admission to intensive care units (ICUs), with invasive mechanical ventilation (IMV), than those without RD: OR 3.72; 95% CI 1.35 to 10.26 (for both outcomes; very low certainty of evidence). CONCLUSION: Patients undergoing pharmacological treatment for IMID seem to present higher chances of requiring admission to ICUs, with IMV. Additional high-quality studies are needed to analyze the effects of different treatments for IMID.
Documentos Relacionados
- Brazilian recommendations on the safety and effectiveness of the yellow fever vaccination in patients with chronic immune-mediated inflammatory diseases
- Immune-mediated thrombocytopenia of malaria.
- Environmental cleaning to prevent COVID-19 infection. A rapid systematic review
- Smell and taste alterations in COVID-19 patients: a systematic review
- Head and Neck Practice in the COVID-19 Pandemics Today: A Rapid Systematic Review